| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.36 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Background: Erythropoietin binds to the erythropoietin receptor to promote the proliferation and differentiation of red blood cells. This hypoxia-induced hormone is produced in adult kidneys with erythropoietin and non-erythropoietic effects. Since current anti-inflammatory therapies are not safe, erythropoietin emerges as a new pharmacological approach reverting the mechanism of inflammation with apparently lower toxicity. AIM: Evaluate the potential anti-inflammatory effect of erythropoietin observed in animal inflammatory disease models. Methods: A systematic review followed PRISMA statements in the electronic database MEDLINE via the PubMed platform. The inclusion criteria were: (1) original articles; (2) studies in animal models where erythropoietin was administered; (3) studies where inflammation was studied and/or evaluated; (4) non-clinical studies in vivo with rodents; and (5) articles published in English. Results: A total of 36 articles met the criteria for qualitative analysis. Exogenous erythropoietin was used in models of sepsis, traumatic brain injury, and autoimmune neuritis with anti-inflammatory effects. The average dose of exogenous erythropoietin was 3000 IU/kg of weight. Erythropoietin was associated with a significant reduction of biomarkers such as immune-related effectors, cytokines, reactive oxygen species, and prostaglandins. Erythropoietin analogues, such as ARA290 or carbamylated erythropoietin, have the crucial advantage of promoting the anti-inflammatory effect without the thromboembolic risk by the proliferation of red blood cells. Conclusion: Erythropoietin is recognized as a multifunctional cytokine with anti-inflammatory properties, showing its significant effect both in acute and chronic murine models of inflammation.
Description
H&TRC authors gratefully acknowledge the FCT/MCTES national support through the UIDB/05608/2020 and UIDP/05608/2020.
Keywords
Bowel inflammatory disease Erythropoietin FCT_UIDB/05608/2020 FCT_UIDP/05608/2020 IPL/2020/cEPO_ESTeSL
Citation
Silva I, Alípio C, Pinto R, Mateus V. Erythropoietin in animal models of inflammation. In: Gastro-Hepato 2021 - Virtual Global Congress on Advances in Gastroenterology and Hepatology, May 24-25, 2021.